My top 10 things to watch Thursday, Aug. 13 1. Producer price index for July came in mostly cooler than expected , on the heels of yesterday’s consumer inflation report matching expectations. Not a whole lot of change in market expectations for the Federal Reserve’s next move in September, with about 64% odds of rates being kept steady. S & P futures were modestly higher this morning. 2. Investors in Anthropic expect the AI lab to seek a valuation of at least $2 trillion in a potential IPO this fall, the Financial Times reported . Where are those investors getting that idea? Some will say everything is out of hand if Anthropic can command $2 trillion, but it’s not far-fetched if they have the financials to back it up. This would exceed SpaceX’s $1.77 trillion valuation in its record-breaking IPO in June. 3. Cisco reported an amazing quarter last night, but then offered an AI revenue guide for this fiscal year that is a fraction of what it should be given the last quarter. No wonder the stock is down 6% premarket. Also, some concerns about gross margins. Is a lot of the growth less-profitable AI hardware? Will dig into this with CEO Chuck Robbins later this morning on CNBC. 4. Big day for the Investing Club today. Our Monthly Meeting for August kicks off at noon ET. Been putting my heart into this one. My partner Jeff Marks and I will be discussing our newest position and going through the rest of our 32-stock portfolio. We’ll also take questions directly from members. Still time to sign up here . 5. JPMorgan resumed coverage of Salesforce with a buy rating, expecting its core business to accelerate in the coming quarters, and arguing AI disruption risk is fairly limited. That potential acceleration is one reason why we’ve held onto this one for the Club. Even without it, JPMorgan said shares are so cheap there’s still more upside to be had. Let’s see what CRM says at its all-important Dreamforce conference next month. The stock has strung together a few good weeks. 6. Oracle was also reinstated with a buy rating at JPMorgan. Same analyst team. After a breathtaking decline from early June into late July, Oracle has started to rebound. Analysts said the rapid buildout of AI infrastructure gives Oracle the opportunity to compete with the cloud hyperscalers ( Microsoft , Amazon and Google ). They acknowledge its capital needs are sizable, but said the valuation discount implies major upside if profits keep growing and the stock’s multiple re-rates higher. 7. Cerebras is plunging 15% this morning after the newly public AI chipmaker issued disappointing quarterly revenue . Cerebras is one of the many challengers seeking to challenge market leader Nvidia . But to me, these numbers solidify Club name Nvidia’s status. Tough crown to steal. Mizuho lowered its Cerebras price target to $300 from $310. Citi went to $320 from $340. Both kept their buy ratings. 8. KeyBanc hiked its price target on Brinker to $275 from $204 after the Chili’s owner issued strong guidance yesterday. Sales trends in the current quarter were encouraging, and KeyBanc said it has greater conviction on the sustainability of mid-single-digit comparable sales growth. Brinker CEO Kevin Hochman will be on “Mad Money” tonight. I also like fellow restaurant chain Texas Roadhouse . Both stocks are working because people know they can get a good meal at a fair price there. 9. Tapestry beat on earnings and revenue, but 2027 earnings guidance underwhelmed. Coach sales were in line and up 14% in constant currency. Another quarter where Kate Spade dragged, with sales down 7%. The stock is down nearly 9% premarket. My preferred luxury play right now is Ralph Lauren . Big fan of what CEO Patrice Louvet is doing there. 10. A lot of love for Abbott . Wolfe Research upgraded the stock to buy from hold, pointing to organic growth improvements and a potential re-rating of shares. Citi raised its price target to $125 from $112. Analysts are more upbeat on medtech after earnings. 2027 estimates for the group seem to be at more reasonable levels. We thankfully exited Abbott last fall, avoiding what had been a rough 2026. Johnson & Johnson gives us medtech exposure now. Need it lower before we buy any more. Sign up for my Top 10 Morning Thoughts on the Market email newsletter for free (See here for a full list of the stocks at Jim Cramer’s Charitable Trust.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust’s portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.
Jim Cramer’s top 10 things to watch in the stock market Thursday
Aug 13, 2026
